MAPK3 and systemic sclerosis: This hypothesis was supported by our data showing that recombinant soluble TGFβ receptor II, an antagonist of TGFβ signaling, was able to block the downregulation of PP2A and to reverse the constitutive phosphorylation of ERK1/2 in cultured SSc fibroblasts.